GC-C Selective Peptides for Upper GI Motility Without Lower GI Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for upper gastrointestinal disorders such as functional dyspepsia and gastroparesis are limited in efficacy and safety, with existing therapies often causing adverse effects on bowel habits like diarrhea.
Innovation Solution
Development of peptides that selectively activate the guanylate cyclase C (GC-C) receptor in the upper gastrointestinal tract, reducing symptoms like pain and bloating without significant effects on the lower GI tract, achieved through specific amino acid sequences and pH-dependent activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat upper gastrointestinal disorders, then symptoms may be alleviated, but adverse effects on bowel habits such as diarrhea occur
Solution Approach 1:
The peptide is designed to selectively activate GC-C receptors in the upper gastrointestinal tract while having minimal effect on lower GI tract receptors. This spatial selectivity is achieved through the peptide's structural characteristics and pH-dependent activity, allowing it to treat upper GI disorders without causing lower GI adverse effects like diarrhea
Solution Approach 2:
The peptide's activity is pH-dependent, with optimal activation occurring at the pH conditions found in the upper GI tract. This parameter-based selectivity allows the peptide to differentiate between upper and lower GI environments, providing therapeutic effect where needed while avoiding harmful effects in other regions
2Productivity
If GC-C agonists are used to increase GI motility, then upper GI symptoms improve, but lower GI function is significantly affected
Solution Approach 1:
The peptide's action is segmented by location - it selectively targets and activates GC-C receptors in the upper gastrointestinal tract while sparing those in the lower GI tract. This spatial segmentation of pharmacological effect allows increased motility where needed without disrupting lower GI function
Solution Approach 2:
The peptide acts as a selective intermediary that mediates the activation of GC-C receptors only in specific regions. Through its molecular structure and pH-dependent properties, it serves as a targeted mediator that triggers motility enhancement in the upper GI tract without propagating effects to the lower GI tract
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively alleviate upper GI symptoms by increasing motility and reducing pain and bloating without causing pronounced effects on bowel habits, such as diarrhea, thus improving treatment outcomes for patients with functional dyspepsia and gastroparesis.
Implementation Method 1
achieved through specific amino acid sequences and pH-dependent activity
Data Source
Figure 1
AI summary
Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.